Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study

Journal of Clinical Oncology

Volumn 23, Issue 30, 2005, Pages 7546-7554

  Freedland, Stephen J ^a   Isaacs, William B ^a   Platz, Elizabeth A ^a   Terris, Martha K ^a   Aronson, William J ^a   Amling, Christopher L ^a   Presti Jr , Joseph C ^a   Kane, Christopher J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CHEMICAL ANALYSIS; DATA BASE; HUMAN; INFORMATION RETRIEVAL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; ORGAN WEIGHT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE; PROSTATE CANCER; PROSTATE WEIGHT; PROSTATECTOMY; RISK FACTOR; SEMINAL VESICLE; TRANSRECTAL ULTRASONOGRAPHY; BLOOD; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SURVIVAL RATE;

HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 85047699965     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.525     Document Type: Article

References (46)

1. Marker PC, Donjacour AA, Dahiya R, et al: Hormonal, cellular, and molecular control of prostatic development. Dev Biol 253:165-174, 2003
2. Isaacs JT, Coffey DS: Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 108:445-453, 1981
3. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349: 215-224, 2003
4. Noldus J, Ferrari M, Prestigiacomo A, et al: Effect of flutamide and flutamide plus castration on prostate size in patients with previously untreated prostate cancer. Urology 47:713-718, 1996
5. Chodak GW, Vogelzang NJ, Caplan RJ, et al: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer: The Zoladex Study Group. JAMA 265:618-621, 1991
6. Ribeiro M, Ruff P, Falkson G: Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Am J Clin Oncol 20:605-608, 1997
7. Chen SS, Chen KK, Lin AT, et al: The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis. BJU Int 89:710-713, 2002
8. Iversen P, Rasmussen F, Christensen IJ: Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 157:41-47, 1994
9. Oefelein MG, Agarwal PK, Resnick MI: Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171:1525-1528, 2004
10. Zagars GK, Pollack A, von Eschenbach AC: Serum testosterone: A significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49:327-334, 1997
11. D'Amico AV, Chen MH, Malkowicz SB, et al: Lower prostate specific antigen outcome than expected following radical prostatectomy in patients with high grade prostate and a prostatic specific antigen level of 4 ng/ml or less. J Urol 167:2025-2030, 2002
12. Massengill JC, Sun L, Moul JW, et al: Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169:1670-1675, 2003
13. Hoffman MA, DeWolf WC, Morgentaler A: Is low serum free testosterone a marker for high grade prostate cancer? J Urol 163:824-827, 2000
14. Schatzl G, Madersbacher S, Thurridl T, et al: High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47:52-58, 2001
15. Monda JM, Myers RP, Bostwick DG, et al: The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 46:62-64, 1995
16. Freedland SJ, Amling CL, Dorey F, et al: Race as an outcome predictor after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60:670-674, 2002
17. Freedland SJ, Sutter ME, Dorey F, et al: Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Urology 61:365-369, 2003
18. Freedland SJ, Presti JC Jr, Terris MK, et al: Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the SEARCH database. J Urol 169:2129-2135, 2003
19. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
20. Freedland SJ, Aronson WJ, Kane CJ, et al: Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: A report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 22:446-453, 2004
21. Freedland SJ, Presti JC Jr, Kane CJ, et al: Do younger men have better biochemical outcomes after radical prostatectomy? Urology 63: 518-522, 2004
22. Freedland SJ, Wieder JA, Jack GS, et al: Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. J Urol 168:110-115, 2002
23. Walsh PC, Madden JD, Harrod MJ, et al: Familial incomplete male pseudohermaphroditism, type 2: Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291:944-949, 1974
24. Coffey DS, Walsh PC: Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 17:461-475, 1990
25. Berry SJ, Coffey DS, Ewing LL: Effects of aging on prostate growth in beagles. Am J Physiol 250:R1039-R1046, 1986
26. Partin AW, Oesterling JE, Epstein JI, et al: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 145:405-409, 1991
27. Roberts RO, Bergstralh EJ, Cunningham JM, et al: Androgen receptor gene polymorphisms and increased risk of urologic measures of benign prostatic hyperplasia. Am J Epidemiol 159:269-276, 2004
28. Roberts RO, Jacobson DJ, Girman CJ, et al: Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. Am J Epidemiol 157:784-791, 2003
29. Hammarsten J, Hogstedt B: Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol 39:151-158, 2001
30. Makridakis NM, Reichardt JK: Molecular epidemiology of androgen-metabolic loci in prostate cancer: Predisposition and progression. J Urol 171:525-528, 2004
31. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94:3320-3323, 1997
32. Merrick GS, Wallner KE, Butler WM: Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 169:1643-1652, 2003
33. Nixon RG, Meyer GE, Brawer MK: Differences in prostate size between patients from University and Veterans Affairs Medical Center populations. Prostate 38:144-150, 1999
34. Terris MK, Prestigiacomo AF, Stamey TA: Comparison of prostate size in university and Veterans Affairs Health Care System patients with negative prostate biopsies. Urology 51:412-414, 1998
35. D'Amico AV, Whittington R, Malkowicz SB, et al: A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 52:631-636, 1998
36. Foley CL, Bott SR, Thomas K, et al: A large prostate at radical retropubic prostatectomy does not adversely affect cancer control, continence or potency rates. BJU Int 92:370-374, 2003
37. Stamey TA, Yemoto CM, McNeal JE, et al: Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol 163: 1155-1160, 2000
38. Carter CA, Donahue T, Sun L, et al: Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21:4001-4008, 2003
39. Epstein JI, Walsh PC, Carter HB: Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol 166:1688-1691, 2001
40. Thompson IM, Klein EA, Lippman SM, et al: Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 44: 650-655, 2003
41. Skarda J: Bioassay of steroid hormone agonist and antagonist activities of anti-androgens on mammary gland, seminal vesicles and spleen of male mice. J Vet Med A Physiol Pathol Clin Med 50:204-212, 2003
42. Kousteni S, Chen JR, Bellido T, et al: Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science 298:843-846, 2002
43. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591-1597, 1999
44. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441-1445, 1997
45. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003
46. Ward JF, Blute ML, Slezak J, et al: The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170:1872-1876, 2003